Kidney Cancer | Tumor

CURE’s kidney cancer page is an extensive resource of cancer information featuring the latest kidney cancer news, expert oncologist insights on the latest cancer treatments, oncology research, advocacy efforts, and medical data on kidney cancer.

Kidney Cancer's Affect On the Risks of Coronavirus

June 8th 2020

How kidney cancer affects the risks of coronavirus.

Kidney Cancer Association Addresses Changes Amid Coronavirus

June 8th 2020

A message from the KCA’s CEO and President about COVID-19.

Looking at The World With a New Lens

June 6th 2020

Kidney cancer changed how Tracie saw her world.

Riding For Kidney Cancer

June 6th 2020

On his motorcycle, Stewy rides for kidney cancer.

Getting to Ring the Bell

June 6th 2020

A clinical trial and a positive attitude helped Bill Brown ring the bell.

Finding Your Own Answers to Kidney Cancer

June 6th 2020

Dawne Gee worked hard to get answers about her kidney cancer.

Keytruda-Inlyta Combination Continues to Show Superior Survival Outcomes in Advanced Renal Cell Carcinoma

June 5th 2020

“These results continue to support pembrolizumab (Keytruda) plus axitinib (Inlyta) as a standard of care for patients with previously untreated advanced RCC,” said lead study author Dr. Elizabeth R. Plimack.

MK-6482 Shows Promise in von Hippel-Lindau Disease-Associated Renal Cell Carcinoma

May 30th 2020

The HIF-2a Inhibitor induced clinical responses among patients with von Hippel-Lindau disease–associated kidney cancer, according to results presented at the 2020 ASCO Virtual Scientific Program.

Fotivda Improves Survival in Relapsed, Refractory Metastatic Renal Cell Carcinoma

May 29th 2020

When compared with Nexavar, Fotivda showed improved progression-free survival, and a more manageable safety profile for patients with relapsed or refractory metastatic renal cell carcinoma.

Approval of Keytruda Every Six Weeks a 'Welcome Change' for Patients With Cancer

May 21st 2020

“Those who are doing well and are stable in terms of safety and tolerability can come into the office less often,” Dr. David R. Spigel, said. “(This is) a big win.”

Tolerability of Fotivda Is Key in Treating Relapsed, Refractory Renal Cell Carcinoma

May 20th 2020

Dr. Brian Rini discussed the benefits of treating patients with relapsed or refractory renal cell carcinoma with the vascular endothelial growth factor tyrosine kinase inhibitor.

Opdivo-Yervoy Combination Continues to Show Superior Long-Term Outcomes in Renal Cell Carcinoma

May 11th 2020

Further follow up of the CheckMate-214 trial continues to show the superior long-term outcomes of Opdivo and Yervoy in treatment of patients with advanced renal cell carcinoma.

Novel Combination Improves Survival in Untreated Advanced Renal Cell Carcinoma

May 8th 2020

Patients with advanced renal cell carcinoma may soon have a new option in the novel combination of Opdivo (nivolumab) and Cabometyx (cabozantinib).

CURE Community Vlog: Staying Healthy During the COVID-19 Pandemic

April 29th 2020

“I’m not going to give up on that just because of this pandemic. Health is most important, as it should be for us cancer survivors.”

FDA Approves Every Six-Week Dose of Keytruda Across All Indicated Cancer Types

April 29th 2020

Keytruda, an immunotherapy that treats a variety of adult cancers, can now be given at a higher dose that requires fewer visits to clinics for infusions to support social distancing during the COVID-19 pandemic.

CURE Community Vlog: Taking Control Over a Cancer Diagnosis

April 21st 2020

“I thought, you know what I have control right now: if I'm going to laugh, if I'm going to enjoy my family, or if I'm going to hide in a corner and cry all day. I'm not going to do that. I'm not going to let cancer do that to me.”

Best Approaches for Patients with Metastatic Renal Cell Carcinoma

March 26th 2020

Once a patient progresses following initial treatment for kidney cancer, one expert says TKIs are the next step in therapy.

Combination Immunotherapy Use in Metastatic Kidney Cancer

March 24th 2020

Different combinations of immunotherapy with chemotherapy are helping patients with renal cell carcinoma live longer.

Rates of Cancer, Diabetes and Heart Disease Are Higher in Transgender Men Than in Cisgender Men

March 23rd 2020

The first study to look at cancer prevalence in transgender people and examine the health of transgender cancer survivors also found concerning health trends among transgender women and gender nonconforming people.

The Kidney Cancer Association Seeks Applicants for $1.3 Million in Grant Funding

March 20th 2020

Young Investigator and Advanced Discovery Awards will advance kidney cancer research, as the Kidney Cancer Association opens up its grant applications.

Survival Rates in Renal Cell Carcinoma Vary for African American Patients

March 11th 2020

African American race was associated with longer survival in non-clear cell metastatic renal cell carcinoma compared with Hispanic and Caucasian patients.

Friday Frontline: Cancer Updates, Research and Education on February 28, 2020

February 28th 2020

From New Jersey Governor Phil Murphy announcing he will undergo surgery to remove a potentially cancerous tumor on his kidney to an NHL team granting a 15-year-old fan with cancer the ultimate wish, here’s what is making headlines in the cancer space this week.

Combination Therapies Open New Doors in Renal Cell Carcinoma Studies

February 26th 2020

Utilizing the data of the CheckMate 9ER trial, researchers believe that combination therapies in the treatment of patients with renal cell carcinoma are the future of the landscape.

New Issue Alert: CURE Winter 2020

February 25th 2020

Here’s a look at what’s inside our 2020 Winter issue.

Aiming for Long Term Success in Kidney Cancer Treatment

February 24th 2020

Treatments for renal cell carcinoma are showing effectiveness in the short term, but with the help of new trials, researchers are looking to expand their impact for long term treatment.

Immune Checkpoint Inhibition Could Be the Future of Renal Cell Carcinoma Treatment

February 24th 2020

The landscape for patients with renal cell carcinoma could potentially change as the use of immune checkpoint inhibition shows promise for these patients.

Novel Agent Shows Promise in Patients with Clear Cell Renal Cell Carcinoma

February 19th 2020

MK-6482 demonstrated an objective response rate of 24% among patients with advanced clear cell renal cell carcinoma, according to study findings presented at the 2020 Genitourinary Cancers Symposium.

Long-Term Follow-Up Supports Treatment with Opdivo in Advanced Renal Cell Carcinoma

February 18th 2020

After five years of follow-up, treatment with Opdivo in those with previously treated advanced or metastatic renal cell carcinoma induced superior survival outcomes.

Opdivo-Yervoy Combo Induces Superior Long-Term Outcomes in Patients with RCC

February 18th 2020

More than 50% of patients with previously untreated advanced or metastatic renal cell carcinoma were alive at 42 months after being treated with Opdivo plus Yervoy.

Childhood Body Mass Index Plays a Role in Kidney Cancer Risk as an Adult

February 13th 2020

Children with higher birth weight and body mass index, as well as taller height, are at a greater risk of developing renal cell carcinoma later in life, according to new study findings.

NEXT PAGE
PREVIOUS PAGE